Results 11 to 20 of about 28,270 (206)

The Use of Prasugrel and Ticagrelor in Pipeline Flow Diversion [PDF]

, 2018
Background: Despite the routine clopidogrel/aspirin anti-platelet therapy, complications like thromboembolism, continue to be encountered with PED.
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Eller, MD, Gorge, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA MD, Robert H., Saad, MD, Hassan, Stidd, MD, David, Tjoumakaris, MD, Stavropoula   +9 more
core   +2 more sources

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

Platelets, 2022
The benefits of potent antithrombotic therapy usually come at the expense of a higher risk of bleeding. The efficacy and safety of ticagrelor in elderly East Asian populations remains debated due to the concerns about the imbalance of ischemic and ...
Ziwei Xi, Zifeng Qiu, Jianan Li, Hong Qiu, Tingting Guo, Yong Wang, Jianfeng Zheng, Yanan Gao, Runlin Gao   +8 more
doaj   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Fluorescence quenching-based immunological probe for ticagrelor monitoring

Frontiers in Bioengineering and Biotechnology, 2023
Introduction: Ticagrelor is extensively utilized for the treatment of acute coronary syndromes (ACS), but its platelet aggregation inhibitory effects can potentially result in tissue bleeding, posing a serious risk to patients’ lives.Methods: In this ...
Shengshuo Zhang, Shengshuo Zhang, Yueqing Cheng, Yujie Gao, Yujie Zou, Weiling Xiao, Tianyi Li, Mei Li, Bowen Yu, Jinhua Dong, Jinhua Dong   +10 more
doaj   +1 more source

Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]

, 2018
© The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez, C Varenhorst, D Alexopoulos, D Aradi, D Lindholm, D Zhou, EA Amsterdam, F Franchi, G Parodi, G Parodi, H Sillén, HS Smith, J Kubica, J Kubica, J Li, JH Cornel, JM Siller-Matula, K Butler, K Butler, K Thygesen, M Koziński, M Roffi, P Adamski, P Adamski, P Adamski, P Adamski, P Niezgoda, P Niezgoda, PG Steg, PG Steg, PT O’Gara, R Teng, R Teng, R Teng, R Teng, R Teng, R Teng, RA Lange, S Husted, S James, SE Husted, SS Brar   +41 more
core   +2 more sources

Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease

Platelets, 2019
We performed this study to observe the effects of different doses of ticagrelor and standard-dose clopidogrel on platelet reactivity and endothelial function in diabetic patients with stable coronary artery disease (CAD).
Meijiao He, Dan Li, Yingli Zhang, Danghui Sun, Guangzhong Liu, Yujiao Pan, Jing Shi, Yanyan Li, Shuangli Yin, Yue Li   +9 more
doaj   +1 more source